<DOC>
	<DOCNO>NCT01612936</DOCNO>
	<brief_summary>The specific hypothesis study fundamental difference T effector T regulatory cell response lung allergens allergic asthma ( AA ) compare allergic nonasthmatics ( ANA ) account difference clinical response . We address compare T cell response AA versus ANA subject . These experiment correlate T cell response measure airway physiology use state-of-the art lung image examine mechanism control T cell activation airways AA function airway T regulatory cell AA .</brief_summary>
	<brief_title>T Cell Effector Regulatory Mechanisms Asthma</brief_title>
	<detailed_description>Despite advance medication , allergic disease , include allergic asthma , continue rise prevalence . For reason , need good understand mechanisms allergic disease novel insight modulate allergic inflammation . CD4+ Th2-type lymphocyte seem central pathogenesis allergic disease , level cell Th2 cytokine ( IL-4 , IL-5 IL-13 ) elevate airways allergic asthma patient . The unifying hypothesis project understand mechanism determine critical balance effector regulatory allergen-specific T cell activity asthma lead new approach induce allergen-specific tolerance new therapeutic strategy asthma .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>Subjects Allergic Asthma ( AA subject ) : 1 . All subject baseline FEV1 le 75 % predict value bronchodilator administration . 2 . All subject clinical history allergic symptom cat dust mite allergen positive allergen prick test ( 3 mm diameter great diluent control ) 3 . Lifelong absence cigarette smoking ( lifetime total &lt; 5 packyears none 5 year ) . 4 . Willing able give inform consent . 5 . Expressed desire participate interview principal investigator . 6 . Age 18 50 year . 7 . A methacholine PC20 &lt; 16 mg/ml . 8 . Asthma severity define : require step 3 therapy ( NHLBI Guidelines , 2007 EPR3 , http : //www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf ) , wellcontrolled validated asthma control test ( ACT ) score &gt; 19 one month prior screen visit , able tolerate 2 week stoppage inhale corticosteroid prior Visit 2 . Allergic Nonasthmatic Subjects ( ANA subject ) : 1 . ANA subject history least one following : ( ) allergic rhinitis ( one follow symptom : nasal congestion , sneeze , runny nose , postnasal drainage ) , ( b ) allergic conjunctivitis ( ocular itching , tear and/or swell ) ( c ) contact allergy associate cat dander dust mite positive allergy test allergen . 2 . All subject baseline FEV1 FVC determine characterization visit le 90 % predict value bronchodilator administration . 3 . All subject positive allergy skin prick test cat dander dust mite allergen . 4 . All subject good general health . 5 . Lifelong absence cigarette smoking ( lifetime total &lt; 5 packyears none 5 year ) . 6 . Willing able give inform consent . 7 . Expressed desire participate interview principal investigator . 8 . Age 18 50 year . Subjects Allergic Asthma ( AA subject ) : 1 . Women childbearing potential pregnant ( base urine betaHCG STAT quantitative serum hCG test ) , sexually active use contraception , seek become pregnant , nursing . 2 . The presence spontaneous asthmatic episode clinical evidence upper respiratory tract infection within previous 6 week . 3 . Participation research study involve drug biologic 30 day prior study . 4 . Intolerance albuterol , atropine , lidocaine , fentanyl , midazolam . 5 . Antihistamines within 7 day screen visit . 6 . Presence diabetes mellitus , congestive heart failure , ventricular arrhythmia , history cerebrovascular accident , renal failure , history anaphylaxis , cirrhosis . 7 . Use systemic steroid , increase use inhaled steroid , beta blocker MAO inhibitor visit asthma exacerbation within 1 month screen visit . 8 . Antibiotic use respiratory disease within 1 month characterization visit respiratory tract infection within 6 week bronchoscopy visit . 9 . A history asthmarelated respiratory failure require intubation . 10 . Quantitative skinprick test positive reaction allergen concentration 0.056 BAU AU/ml . 11 . Subjects high possibility poor compliance study . 12 . Have history cigarette smoking within past 5 year &gt; 5 pack year total . 13 . Having secondhand cigarette smoke exposure indoor furry pet except case dog , subject allergic dog subject negative skin test dog . 14 . Other lung disease , sarcoidosis , bronchiectasis active lung infection . 15 . Use Xolair ( omalizumab antiIgE monoclonal antibody ) 6 month . 16 . Immunotherapy cat dust mite extract past . 17 . Use prophylactic aspirin cardiovascular disease 18 . NonEnglish speaker Allergic Nonasthmatic Subjects ( ANA subject ) : 1 . A history asthma . 2 . Exclusion criterion # 1 , 38 10 18 ( AA ) . 3 . A methacholine PC20 &lt; 16 mg/ml . Additional exclusion Criteria Specific PET Imaging : 1 . Anyone unable lay flat scanner table imaging . 2 . We exclude severely morbidly obese subject ( BMI &gt; 32 ) poor quality image obtain weight restriction scanner . 3 . Those diffuse capacity &lt; 80 % predict ( know ) , 4 . Subjects know exposure agent associate pulmonary disease ( i.e . asbestos , silica ) 5 . Subjects research relate radiation exposure great 15 mSv within past year exclude . 6 . Individuals know allergy hypersensitivity FDG exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Allergic</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Constriction</keyword>
	<keyword>Airway</keyword>
	<keyword>Challenge</keyword>
	<keyword>Chemokines</keyword>
</DOC>